Skip to content

A CLINICAL TRIAL ON AYURVEDIC PANCHAKARMA THEREPY IN EXESSIVE MENSTRUAL FLOW

A comparative clinical study of Virechana Karma and Drakshadi churna along with Matra Basti in the management of Asrigdara w.s.r. to Abnormal Uterine Bleeding

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/039967
Enrollment
30
Registered
2022-02-02
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N921- Excessive and frequent menstruation with irregular cycle

Interventions

Intervention1: Virechana karma along Drakshadi churna and Matra basti: Group A(Investigator Drug): Will be treated by Virechana with Trivritalehya along with matra basti and Drakshadi Churna. Dose- 3

Sponsors

National institute of Ayurveda Jaipur Rajasthan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients complaining of Asrigdara having any two of the following symptoms: Heavy menstrual bleeding. Prolonged menstrual bleeding. Inter menstrual bleeding. 2.Hb level equal or more than 8 gm/dl 3.Age between 12 year to 50 years

Exclusion criteria

Exclusion criteria: 1. Pregnant woman 2. Patients having bleeding due to abortion. 3. Ectopic Pregnancy. 4. Patients having any systemic diseases. 5. Patients having coagulation disorders. 6. Patients having bleeding after menopause. 7. Any type of malignancy. 8. Patients having STDs. 9. Patients using IUCDs. 10.Thyroid hormones abnormalities 11.Uterine and pelvic pathology like -Polyps, Endometrial T.B, Fibroid, Adenomyosis, PID etc.

Design outcomes

Secondary

MeasureTime frame
Improvement in quality of life. Timepoint: 8 WEEKS

Primary

MeasureTime frame
Achievement of normal menstruationTimepoint: 8 WEEKS

Countries

India

Contacts

Public ContactDr Hetal H Dave

National institute of Ayurveda Jaipur Rajasthan

hetaldave2406@gmail.com9251758867

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026